References
- Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid. 2002;12(10):855–860.
- Bahn RS. Graves’ ophthalmopathy. New England J Med. 2010;362:726–738.
- Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves’ ophthalmopathy patients. Clin Endocrinol (Oxford). 2003;58(3):280–287.
- Eckstein AK, Plicht M, Lax H, Neuhauser M, Mann K, Lederbogen S. Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metabolism. 2006;91(9):3464–3470.
- Garrity JA, Bahn RS. Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol. 2006;142(1):147–153.
- Aniszewski JP, Valyasevi RW, Bahn RS. Relationship between disease duration and predominant orbital T cell subset in Graves’ ophthalmopathy. J Clin Endocrinol Metabolism. 2000;85(2):776–780.
- Looi A, Gascoyne RD, Chhnaabhai M, Connors JM, Rootman J, White VA. Mantle cell lymphoma in the ocular adnexal region. Ophthalmology. 2005;112(1):114–119.
- Abdullah A, Elsamaloty H, Patel Y, Chang J. CT and MRI findings with histopathologic correlation of a unique bilateral orbital mantle cell lymphoma in Graves’ disease: a case report and brief review of literature. J Neurooncology. 2010;97(2):279–284.
- Min HY, Liu XP, Jiang RX, Lian L, Hu TS. Treatment of thyroid-associated ophthalmopathy: comparative study between prednisone and COP therapy. Zhonghua Yan Ke Za Zhi. 2005;41(9):781–785.
- Salvi M, Vannucchi G, Curro N, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metabolism. 2015;100(2):422–431.
- Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metabolism. 2015;100(2):432–441.
- Minakaran N, Ezra DG. Rituximab for thyroid-associated ophthalmopathy. Cochrane Database Syst Rev. 2013;31(5):CD009226.